Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 6.8% in March

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 14,200 shares, a growth of 6.8% from the March 15th total of 13,300 shares. Based on an average trading volume of 18,300 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.1% of the shares of the company are short sold.

Armata Pharmaceuticals Price Performance

Shares of NYSEAMERICAN ARMP opened at $2.50 on Thursday. The firm has a market capitalization of $90.38 million, a PE ratio of -1.26 and a beta of 0.85. Armata Pharmaceuticals has a fifty-two week low of $1.07 and a fifty-two week high of $5.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.55) earnings per share for the quarter. Armata Pharmaceuticals had a negative net margin of 1,524.51% and a negative return on equity of 280.95%. The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.68 million. As a group, equities research analysts predict that Armata Pharmaceuticals will post -1.34 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a report on Friday, March 22nd.

Hedge Funds Weigh In On Armata Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Armata Pharmaceuticals during the fourth quarter worth about $25,000. HRT Financial LP bought a new stake in Armata Pharmaceuticals during the fourth quarter worth about $52,000. Renaissance Technologies LLC lifted its stake in Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company’s stock worth $91,000 after purchasing an additional 3,900 shares during the last quarter. Northern Trust Corp bought a new stake in Armata Pharmaceuticals during the first quarter worth about $95,000. Finally, Vanguard Group Inc. lifted its stake in Armata Pharmaceuticals by 51.9% during the third quarter. Vanguard Group Inc. now owns 90,969 shares of the company’s stock worth $273,000 after purchasing an additional 31,079 shares during the last quarter. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.